

Special Issue

Pathology and Treatment of Triple-Negative Breast Cancer

Message from the Guest Editor

Special Issue on "Triple Negative Breast Cancer: From Pathology to Treatment" in Breast Cancer Research. TNBC, an aggressive breast cancer subtype lacking ER, PR, and HER2 expression, presents diagnostic and treatment challenges. We seek original research, reviews, and clinical studies on TNBC, covering molecular profiling, biomarkers, tumor microenvironment, targeted therapies, surgical techniques, and radiation therapy. Rigorous peer review will ensure scientific quality. Researchers, clinicians, and breast cancer experts are encouraged to contribute. Our goal is to advance personalized treatment strategies. Contact us for assistance or further information. We eagerly await your valuable submissions.

Guest Editor

Dr. Ramadevi Subramani

Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA

Deadline for manuscript submissions

31 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/187523

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)